Today the United States (U.S.) Court of Appeals for the Federal Circuit
issued a ruling that affirms the preliminary injunction ordered by the
U.S. District Court in Boston barring Roche from selling its
pegylated-erythropoietin (peg-EPO) product MIRCERA in the U.S.
Amgen (NASDAQ:AMGN) issued the following statement regarding today’s
ruling by the Court of Appeals:
Amgen is pleased that the Court of Appeals has affirmed the preliminary
injunction barring Roche from selling its peg-EPO product in the U.S. in
violation of Amgen’s erythropoietin (EPO)
patents. Last week, the District Court ruled that Amgen is entitled to a
permanent injunction and upheld the prior jury verdict and court rulings
regarding the infringement, validity and enforceability of 10 claims of
four of Amgen’s patents.
About Amgen
Amgen discovers, develops, manufactures and delivers innovative human
therapeutics. A biotechnology pioneer since 1980, Amgen was one of the
first companies to realize the new science’s
promise by bringing safe and effective medicines from lab, to
manufacturing plant, to patient. Amgen therapeutics have changed the
practice of medicine, helping millions of people around the world in the
fight against cancer, kidney disease, rheumatoid arthritis and other
serious illnesses. With a deep and broad pipeline of potential new
medicines, Amgen remains committed to advancing science to dramatically
improve people’s lives. To learn more about
our pioneering science and our vital medicines, visit www.amgen.com.
Amgen
Emma Hurley, 805-447-7845 (media)
Arvind Sood,
805-447-1060 (investors)
